MA-RHINOSTICS
9.6.2021 14:02:09 CEST | Business Wire | Press release
Safeguard DNA Diagnostics Inc, SDDI, one of the largest chains of infectious disease laboratories in the Philippines, has introduced COVID sample collection using the Rhinosticsᵗᵐ dry nasal and nasopharyngeal collection swabs. The dry swabs are being introduced at its facilities in Metro Manila, Davao and Negros Occidental. In addition, SDDI will act as the exclusive distributor of Rhinostics in the Philippines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005070/en/
Rhinostics Inc. is a Harvard University spinout company launched to bring new materials and designs for improved sample collection for COVID and broader non-COVID respiratory testing. The Rhinosticsᵗᵐ swabs received a U.S. Emergency Use Authorization (EUA) for COVID sample collection. These swabs allow more comfortable collection, dry shipment and transport without viral transport media.
Paul Jochico, co-Founder and Director of Safeguard DNA Diagnostics, Inc. commented, “We are excited to bring the Rhinostics’ innovative sample collection swabs to the Philippines, to offer our people a more comfortable collection combined with strong assay performance. The dry swabs are more robust and offer lower risk for contamination during collection and transport than VTM and saliva collection devices. Continued COVID testing will help keep more people safe until vaccinations can become widespread in the Philippines.”
George Aaron, CEO and Chairman of Safeguard Biosystems Holdings Ltd, the joint venture partner in SDDI, remarked, “The opportunity to repurpose our molecular microbiology laboratory in Manila provided significant benefits to the people of the Philippines during this unfortunate pandemic. Safeguard remains committed to bringing innovative products for the diagnosis of infectious disease into SDDI’s operations.”
“We could not ask for a better partner to implement our collection swab technology in the Philippines, bringing the newest technology for dry collection, transport and assay performance to the country. SDDI remains an innovator in the diagnostics space in the Philippines, bringing newest technologies to market,” said Cheri Walker, Chief Executive Officer of Rhinostics.
About Safeguard DNA Diagnostics, Inc
Safeguard DNA Diagnostics Inc. (SDDI) is a Philippine Joint Venture company with an equal partnership between Safeguard Biosystems and the interests of Paul Jochico, established to provide Molecular Microbiology diagnostic laboratory services. It delivers rapid detection and identification to COVID-19 and other infectious diseases for the Philippine population.
About Safeguard Biosystems
Safeguard Biosystems is an international molecular diagnostics group that has developed a low cost, high-throughput, molecular diagnostic technology platform. The system enables rapid identification by DNA of the most prevalent bacterial and fungal pathogens directly from blood. Clinical samples can be tested from matrices such as whole blood, urine, peritoneal fluid, and swabs
Safeguard Biosystems is a UK company, incorporated in 2006 and headquartered in Northvale, New Jersey. Safeguard Biosystems’ technology has also been adapted to provide innovative pathogen solutions for Dairy, delivering practical solutions for advanced dairy industry challenges to ensure safe dairy food and healthy herds.
About Rhinostics Inc.:
Rhinostics commercializes simple and elegant solutions to bring better materials, efficiencies and cost savings to the laboratory workflow. The RHINOstic™ automated nasal swab provides features that increase sample throughput by more than 10-fold while removing labor and errors from the laboratory workflow. The swab is integrated onto a cap that can be automated for removal from the tube and rapid accessioning using the 2D barcode on the bottom of the tubes. The product provides an immediate impact to increasing COVID testing efficiencies while being applicable to broader respiratory viral, bacterial, and genetic testing using the polymerase chain reaction (PCR) and next generation sequencing (NGS). In addition, the company offers both a standard nasal swab and nasopharyngeal swab that allow dry shipment, sample concentration and better assay performance. The Rhinostics suite of collection products are registered as Class I exempt medical devices with the FDA and are available for purchase. To learn more, visit https://www.rhinostics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005070/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
T964 Named as Uptime Institute Business Partner to Power Iraq’s Digital Infrastructure29.7.2026 09:02:00 CEST | Press release
Agreement signed at U.S.-Iraq Business Summit brings the world’s most trusted digital infrastructure standards to Iraq Uptime Institute and Tech964 Holding Limited (T964), Iraq’s leading digital infrastructure company, today announced a landmark strategic partnership to accelerate Iraq’s digital transformation. The partnership combines the world’s leading authority in digital infrastructure standards with the company building the critical infrastructure underpinning Iraq’s digital economy. The agreement was signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi, at a historic summit that produced more than 50 agreements valued at over USD $60 billion and marked a powerful new era of economic cooperation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728066813/en/ T964 named as Uptime Institut
ELFA Vape Aerosols Less Harmful Than Cigarette Smoke: Study29.7.2026 09:00:00 CEST | Press release
Levels of 17 analytes usually found in cigarette smoke tested in aerosols from ELFBAR ELFA pods 10 harmful constituents below detectable levels, with formaldehyde and acetaldehyde up to 99.9%* lower than those in cigarette smoke Metals detected well below safety thresholds Complete switching to ELFA significantly reduces or brings to zero adult users’ exposure to harmful constituents Levels of 17 constituents in aerosols from ELFA, a pod system vape by ELFBAR, are undetected or substantially lower than those in cigarette smoke, reveals the latest peer-reviewed study published by iScience, a scientific journal. Aerosols in this study are generated by facilities under standardized laboratory conditions. The tests involve 17 cigarette smoke-related analytes during vaporization of vape liquid from ELFA’s pods in four flavors, including Super Tobacco, Spearmint, Strawberry Ice and Watermelon. Findings indicate that adult smokers completely transitioning to ELFA pod system could reduce, or e
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants29.7.2026 09:00:00 CEST | Press release
François Romaneix is appointed Chairman of the Board of Directors.Prof. Philippe Leboulch joins the Board of Directors and the Scientific Advisory Board.Prof. Alain Fischer becomes Chairman of the Scientific Advisory Board.Isabelle Buckle and Tom Tice are appointed to the Board of Directors. PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation). The Board of Directors of PK MED welcomes four key new members: François Romaneix, appointed Chairman of the Board of Directors.
OpenGate Capital Executes Agreement to Acquire Merak, the Global Rail HVAC Business of Knorr-Bremse29.7.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Merak, the global rail HVAC business of Knorr-Bremse, a publicly listed German industrial company. Terms of the transaction were not disclosed. Headquartered in Getafe, Spain, Merak is a leading global provider of HVAC systems for rail vehicles, with facilities across Spain, Austria, Australia, the United States, China and India. The company offers a comprehensive portfolio of HVAC solutions spanning original equipment, aftermarket services, spare parts, system modernization and overhaul. Built on more than 60 years of engineering expertise, Merak serves a global installed base and maintains long standing relationships with many of the world's leading rolling stock manufacturers. "Merak is a high quality business with a market leading position, differentiated technology and a global customer base built over decades," said Joshua Adams, Partner at OpenGate Ca
Bureau Veritas: Delivering on Our Commitments With Higher Sequential Organic Growth in Q2 and Continuous Margin Improvements29.7.2026 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): H1 2026 key figures1 › Revenue of EUR 3,258.4 million in H1 2026, up 2.1% year-on-year and up 5.0% organically (with a sequential improvement in Q2 2026 at 5.5% organic growth), › Adjusted operating profit of EUR 506.5 million, up 3.1% versus EUR 491.5 million in H1 2025, representing an adjusted operating margin of 15.5%, up 15 basis points year-on-year and up 29 basis points at constant currency, › Operating profit of EUR 430.8 million, down 16.0% versus EUR 513.1 million in H1 20252, › Adjusted net profit of EUR 303.8 million, up 3.9% versus EUR 292.4 million in H1 2025, › Adjusted EPS stood at EUR 0.68 in H1 2026, with a 4.8% increase on a reported basis versus H1 2025 (EUR 0.65 per share) and 9.8% at constant currency, › Attributable net profit of EUR 237.9 million, down 26.2% versus EUR 322.3 in H1 2025, › Free Cash Flow of EUR 157.7 million, up 3.2% organically, and down 6.1% year-on-year due to forex evolutions, › Adjusted net debt/EBITDA ratio stoo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom